News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2019

31 October, 2019 Trading in PledPharma's shares commences today on the Nasdaq Stockholm main market News Corporate Information Other Corporate Information English Regulatory Listing Regulation IR Optional
29 October, 2019 PledPharma publishes prospectus in connection with the list change to Nasdaq Stockholm’s main market News Corporate Action Prospectus English Regulatory Listing Regulation IR Optional
23 October, 2019 Interim report January-September 2019 News English Regulatory MAR Report Interim Q3 IR Optional
21 October, 2019 Nomination Committee appointed for the 2020 Annual General Meeting in PledPharma News Corporate Information Nomination Committee English Regulatory Listing Regulation IR Optional
16 October, 2019 PledPharma approved for listing on Nasdaq Stockholm News Corporate Action Other English Regulatory MAR IR Optional
21 August, 2019 Half-Year report January-June 2019 News English Regulatory MAR Report Interim Q2 IR Optional
21 May, 2019 PledPharma completes a Directed New Share Issue of 4,866,665 shares, raising proceeds of SEK 91 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
21 May, 2019 PledPharma announces intention of a Directed New Share Issue News Corporate Action Shares Issuance English Regulatory MAR IR Optional
7 May, 2019 Report from the Annual General Meeting of PledPharma News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
6 May, 2019 Interim report January-March 2019 News English Regulatory MAR Report Interim Q1 IR Optional
8 April, 2019 NOTICE OF ANNUAL GENERAL MEETING OF PLEDPHARMA AB News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
8 April, 2019 PledPharma’s 2018 annual report published News English Regulatory Listing Regulation Report Annual IR Optional
18 March, 2019 PledPharma’s drug candidate Aladote® granted Orphan Drug Designation News Corporate Action Other English Regulatory MAR IR Optional mfn-cus-aladote
21 February, 2019 Year-end Report January-December 2018 News English Regulatory MAR Report Interim Yearend IR Optional mfn-cus-aladote mfn-cus-pledox

Calendar and upcoming reports

May 3, 2024
Interim Report Q1 2024 (7:00am CEST)

May 6, 2024
Annual General Meeting

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com